Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences.

@article{Siddoway1987PolymorphismOP,
  title={Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences.},
  author={L. Siddoway and K. Thompson and C. Mcallister and T. Wang and G. Wilkinson and D. Roden and R. Woosley},
  journal={Circulation},
  year={1987},
  volume={75 4},
  pages={
          785-91
        }
}
The relationship between debrisoquine metabolic phenotype and the pharmacokinetics and pharmacodynamics of propafenone was studied in 28 patients with chronic ventricular arrhythmias (22 extensive metabolizers [EMs] and six poor metabolizers [PMs] of debrisoquine). EMs were characterized by a shorter propafenone elimination half-life (5.5 +/- 2.1 vs 17.2 +/- 8.0, p less than .001), lower average plasma concentration (Cp) (1.1 +/- 0.6 vs 2.5 +/- 0.5 ng/ml/mg daily dosage, p less than .001), and… Expand
The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine
TLDR
The ability of propafenone to inhibit metabolic pathways exclusive of the CYP2D6 isozyme may be limited and potentiation of disturbing central nervous system adverse effects may occur during combination therapy of propAFenone and lidocaine. Expand
Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine
TLDR
It is concluded that genetic differences in mexiletine oxidation of the debrisoquine-type have an influence on its observed pharmacokinetic variability. Expand
Relationships Between Debrisoquine Hydroxylation and Propafenone Pharmacokinetics
TLDR
In conclusion, the differences in oxidising capacity observed among ‘extensive me-tabolisers’ markedly influence the kinetics of propafenone with relevant clinical implications. Expand
Disposition of propafenone in a poor metabolizer of CYP2D6 with Gilbert's syndrome.
TLDR
Individuals with Gilbert's syndrome who also have a PM phenotype appear to be at no higher risk for toxicity of propafenone than otherwise healthy PMs. Expand
The influence of CYP2D6 activity on the kinetics of propafenone enantiomers in Chinese subjects.
TLDR
It is suggested that CYP2D6 activity contributes to the pharmacokinetic variability of propafenone enantiomers in Chinese subjects. Expand
Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect.
1. Quinidine is a potent inhibitor of the genetically-determined debrisoquine 4-hydroxylation. Oxidation reactions of several other drugs, including the 5-hydroxylation of the new antiarrhythmic drugExpand
Nonlinear kinetics of propafenone metabolites in healthy man
TLDR
The two active metabolites of propafenone showed non-linear kinetics in that both the dose-corrected area under the serum concentration-time curve and the amount excreted in the urine were larger after oral dosing, indicating that it may be due to saturable biliary excretion of the metabolites. Expand
Stereoselective disposition and pharmacologic activity of propafenone enantiomers.
TLDR
During long-term oral therapy, propafenone undergoes stereoselective disposition in patients with either EM or PM, and beta-Blockade during propAFenone therapy is likely related to accumulation of (+)-S-propafen one. Expand
Inhibitory Effects of Propafenone on the Pharmacokinetics of Caffeine in Humans
TLDR
It is suggested that propafenone causes significant inhibition of CYP1A2 activity leading to a decrease in the clearance of caffeine, suggesting that coadministration with an antiarrhythmic agent such as propafanone should be used with caution. Expand
Clinical Pharmacokinetics of Propafenone
TLDR
The drug should be used with caution in patients with serious structural heart disease, as it may cause or aggravate life-threatening arrhythmias and increases the plasma concentrations of digoxin, warfarin, metoprolol and propranolol as well as enhancing their respective pharmacodynamic effects. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 29 REFERENCES
Investigations on the pharmacokinetics of propafenone in man.
TLDR
The results show a dose dependence of bioavailability and maximum plasma concentrations after oral application with over-proportionate increase at higher dose levels yielding bioavailabilities up to 40-50% with single applications of 450 mg. Expand
Genetically determined oxidation capacity and the disposition of debrisoquine.
TLDR
The results of these investigations show that the phenotyping of individuals for debrisoquine oxidation status by means of a single 0-8 h urine sample has a sound kinetic basis and would strongly suggest that the metabolic defect manifested in PM subjects is one of pre-systemic elimination capacity. Expand
Clinical pharmacology of propafenone.
TLDR
It is concluded that propafenone effectively suppresses ventricular arrhythmias and that nonlinear drug accumulation and intersubject variability in elimination of half-life, steady-state mean plasma concentration, and therapeutic concentration indicate a need for individual therapy. Expand
Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations
Interethnic differences in debrisoquin and mephenytoin hydroxylation have been compared between normal white (n = 183) and Japanese (n = 100) subjects with the 8‐hour urinary metaboUc ratio ofExpand
Propafenone disposition kinetics in cardiac arrhythmia
TLDR
The longer t½s and the estimates of steady‐state bioavailability above 100% suggests that clearance decreases during chronic oral dosing, as well as the model‐independent calculated values of clearance, steady‐ state volume of distribution, and terminal t½. Expand
Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardia.
TLDR
Patients with ventricular tachycardia or nonfatal cardiac arrest treated with propafenone (P) had inducible sustained VT at the baseline study, and two are arrhythmia-free during follow-up of 2 and 8 months. Expand
Pharmacological studies on propafenone and its main metabolite 5-hydroxypropafenone.
TLDR
The results show low CNS activity of propafenone which is even lower for the metabolite but which is distinctly higher for lidocaine and - related to the antiarrhythmic potency - for flecainide, too. Expand
Propafenone for refractory ventricular arrhythmias: correlation with drug plasma levels during long-term treatment.
TLDR
Drug efficacy was evaluated as a 70% or greater reduction in VPC frequency with complex VPC abolition in ambulatory monitoring and suppression of nonsustained VT and sustained VT during a follow-up period up to 154 +/- 58 days in groups A and 96 +/- 42 days in group B. Expand
Electrophysiologic and hemodynamic effects of intravenous propafenone in patients with recurrent ventricular tachycardia.
TLDR
An appropriate loading dose of intravenous propafenone such as 2mg/kg followed by 2 mg/min infusion may be given safely and may suppress ventricular tachycardia. Expand
Effect of propafenone in the Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up.
TLDR
In conclusion, propafenone is an effective and well-tolerated antiarrhythmic agent in the long-term management of patients with the Wolff-Parkinson-White syndrome. Expand
...
1
2
3
...